
|Articles|October 1, 2003
Biologics Seek 'Equal Footing' to Current Therapy
New York - The safety and efficacy of the new biologic agents for psoriasis suggest a new treatment strategy that departs from the current stepwise approach, according to Craig L. Leonardi, M.D., clinical associate professor of dermatology, Saint Louis University School of Medicine in Missouri.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Clinicians Weigh Topical Sequencing and Escalation in Complex Atopic Dermatitis Cases
2
Phase 3 STOP-HS Trials Highlight Promise of Oral JAK1 Inhibition for Moderate to Severe Disease
3
Sonelokimab Meets Primary End Point in Phase 3 Psoriatic Arthritis Trial
4
Common Mistakes in Managing Hair Loss and Pigmentary Disorders
5











